引言：工业AI赛道迎来重量级玩家 当前，全球制造业正处于智能化转型的关键节点。根据弗若斯特沙利文报告，中国工业AI解决方案市 场预计将从2024年的人民币58亿元增长至2030年的人民币935亿元，年复合增长率高达58.8%。这一增 长得益于多重因素驱动：首先，中国"十四五"规划明确将人工智能与制造业深度融合作为国家战略；其 次，新能源车、5G/6G通信、机器人等新兴行业对柔性制造、质量追溯与效率提升的需求激增；第三， 制造业劳动力成本上升与全球供应链重构倒逼企业加快自动化、数字化进程。 工业AI的本质是通过数据驱动实现制造系统自优化，但其壁垒远高于消费互联网AI。它要求对工艺参 数、设备兼容性、材料特性等物理知识有深度理解，且依赖高价值、多模态的工业数据训练模型。上海 精智的独特优势在于其通过三大制造板块——先进装备、精密零部件、通讯热管理——积累了覆盖"设 计-生产-运维"全链路的实时数据，形成"制造反哺AI、AI赋能制造"的飞轮效应。 公司核心优势：数据资产与技术沉淀构建深厚护城河，制造与AI的"飞轮效应" 招股书显示，上海精智计划深化三类核心AI产品——排产调度、工艺优化、视觉识别，并探索SaaS化 ...

Core Viewpoint - The company, Gu Han Pharmaceutical (000590.SZ), has stated that its current products and services do not involve AI medical applications. The company is focused on creating a "post-factory" model in the pharmaceutical industry, providing comprehensive lifecycle pharmaceutical services such as R&D, process optimization, and customized production for pharmacies and the pharmaceutical sector [1]. Group 1 - The company is committed to exploring the integration of new technologies with its existing business in response to market developments [1]. - The company aims to provide full lifecycle pharmaceutical services, which include R&D, process optimization, and customized production [1]. - The company emphasizes its dedication to the pharmaceutical industry's "post-factory" model, indicating a strategic focus on enhancing service offerings [1].

Core Viewpoint - The company, Guohan Pharmaceutical, currently does not have any involvement in the AI medical field and is focused on providing comprehensive pharmaceutical services through its "back factory" model [1] Group 1: Company Strategy - Guohan Pharmaceutical is dedicated to creating a "back factory" model in the pharmaceutical industry, offering services such as research and development, process optimization, and customized production for pharmacies and the pharmaceutical sector [1] - The company plans to explore the integration of new technologies with its existing business in response to market developments, although it has not yet ventured into AI medical applications [1]